Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions.
Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions.
复制标题
DOI：
10.3857/roj.2016.34.1.59
复制
发表时间：
2016-03
影响因子：
2.3
通讯作者：
Lee JE
中科院分区：
文献类型：
--
作者：
Lee JW;Lee JE
评价接受局部放疗（LRT）的多发性骨髓瘤（MM）患者症状性骨病变的临床结局。分析了51例患者的87处症状性骨病变，这些病变通过LRT治疗。LRT的中位总剂量为21戈伊（范围：12 - 40戈伊），中位剂量为7次（范围：4 - 20次）。评估LRT的临床结局和影响治疗反应的因素。中位随访时间为66.7周后，87处病变中有85处（97.7%）症状缓解。从LRT开始至症状缓解的中位时间为7天（范围，1至67天）。现场无失败生存期的持续时间范围为1.1至450.9周（中位数为66.7周）。放射剂量或既往和同期化疗的使用与LRT的现场失败无显著相关性（分别为p = 0.354、0.758和0.758）。多发性骨髓瘤患者的症状性骨病变可通过LRT成功治疗。较高的辐射剂量或同时使用化疗可能不会影响现场疾病控制。相对较低的辐射剂量可以缓解MM患者的症状。
To evaluate the clinical outcomes of symptomatic bone lesions in patients with multiple myeloma (MM) who received local radiotherapy (LRT). Fifty-one patients with 87 symptomatic bone lesions treated via LRT were analyzed. LRT was delivered at a median total dose of 21 Gy (range, 12 to 40 Gy) in a median of 7 fractions (range, 4 to 20 fractions). The clinical outcomes of LRT and the factors affecting treatment response were assessed. After a median follow-up time of 66.7 weeks, symptom relief was achieved for 85 of 87 lesions (97.7%). The median time to symptom relief was 7 days from the start of LRT (range, 1 to 67 days). The duration of in-field failure-free survival ranged from 1.1 to 450.9 weeks (median, 66.7 weeks). The radiation dose or use of previous and concurrent chemotherapy was not significantly associated with in-field failure for LRT (p = 0.354, 0.758, and 0.758, respectively). Symptomatic bone lesions in patients with MM can be successfully treated with LRT. A higher radiation dose or the use of concurrent chemotherapy may not influence the in-field disease control. A relatively low radiation dose could achieve remission of symptoms in patients with MM.